Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.
OBJECTIVE
To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ).


METHODS
The case records of women (n = 33) exposed to HCQ during their pregnancies (n = 36) and of 53 control patients from a single lupus pregnancy centre were reviewed to determine lupus activity, obstetric experience, and infant outcome.


RESULTS
HCQ was not apparently teratogenic. Lupus activity and obstetric outcome in the two groups were similar.


CONCLUSIONS
HCQ continuation is probably safe during pregnancy in patients with lupus, but there is no obvious advantage in commencing treatment.
Buchanan
N M
NM
Lupus Pregnancy Clinic, St Thomas' Hospital, London, United Kingdom.
Toubi
E
E
Khamashta
M A
MA
Lima
F
F
Kerslake
S
S
Hughes
G R
GR
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects / Q000627:therapeutic use*; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D006886:Hydroxychloroquine